SphygmoCor in Clinical Practice
AtCor Medical sponsors Satellite Symposium at Renal Physicians Association Annual Meeting.
Itasca, IL (PRWEB) April 05, 2013
AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor® system which measures central aortic blood pressures and arterial stiffness non-invasively, sponsored a satellite symposium entitled; “Application of Central Aortic Pressure and Arterial Stiffness in Clinical Practice” at the US Renal Physicians Associations (RPA) Annual Meeting in New Orleans, LA.
The RPA is a 3,800 member strong specialty physician group focused on the comprehensive management of all aspects of kidney disease and complex hypertension disorders in both the kidney (renal) patient and the general population. The timing of the symposium coincided with the official release in January 2013 by the American Medical Association (AMA) of a Category III CPT (Common Procedural Terminology) reimbursement code (0311T) the SphygmoCor® test.
Faculty presenting at the symposium, all of whom currently utilize the SphygmoCor System in clinical practice, included; Matthew Budoff, MD, FACC, cardiologist, UCLA/LA Biomedical Research Center at Harbor-UCLA Medical Center in Los Angeles, CA; Susan Steigerwalt, MD, nephrologist at St. Clair Specialty Physicians, PC, and director of the Resistant Hypertension Center at Providence Hospital in Detroit, MI; and Raymond Townsend, MD, nephrologist, Professor of Medicine and an Associate Director of the Clinical & Translational Research Center/CTSA at the University of Pennsylvania. Dr. Townsend also presented at the RPA meeting program on Hypertension: New Tools and Technologies to Improve Care, focusing on central pressures and arterial stiffness.
Each speaker demonstrated how central pressure measurement can direct patient management to improve clinical outcomes, citing medical literature and specific case studies from their own patient populations.
“I was pleased to speak at this symposium to convey the critically important information available through SphygmoCor testing. Non-invasive central blood pressure aids in my decision in determining who should be pharmacologically treated in borderline hypertensive patients as well as guides therapy in the complex and resistant hypertensive patients,” said Dr. Susan Steigerwalt, MD.
Duncan Ross, AtCor Medical CEO, stated “this well attended symposium at the annual RPA meeting demonstrates our commitment to providing the nephrology community with improved diagnostic tools to improve blood pressure management as well as reduce the progression of disease and complications.”
About AtCor Medical
AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company´s SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 3,100 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies, and the company´s technology have been featured in over 700 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at http://www.atcormedical.com
For further information, please contact:
Duncan Ross — AtCor Medical CEO
+1 (630) 228 8873
Peter Manley — AtCor Medical CFO
+61 (2) 9874 8761
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/4/prweb10599126.htm